share_log

Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $558

Benzinga ·  Aug 3 03:34  · Ratings

Guggenheim analyst Debjit Chattopadhyay maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $450 to $558.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment